Taybi M, Bourkhime H, Khammar Z, Alami Drideb N, Berrady R, Benmiloud S, Elfakir S, Bouguenouch L, Tahiri L, Chbani L, Hammas N
Department of Pathology, HASSAN II University Hospital, Fez, Morocco.
Laboratory of Biomedical and Translational Research, Faculty of Medicine and Pharmacy, Sidi Mohammed Ben Abdellah University, Fes, Morocco.
Clin Pathol. 2024 Oct 8;17:2632010X241289778. doi: 10.1177/2632010X241289778. eCollection 2024 Jan-Dec.
The most prevalent subtype of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). Germinal center B-cell (GCB) and non-germinal center B-cell (non GCB) are the two main biologically different molecular subtypes identified utilizing an immunohistochemistry-based approach.
Our objective in this study is to analyze the impact of immunohistochemical subtypes of DLBCL (GCB or non GCB) on demographic and clinicopathological parameters, response to chemotherapy and survival outcomes.
This is a retrospective study including 106 cases of DLBCL collected in the department of pathology, Hassan II university hospital, Fez (Morocco), over a period of 12 years (January 2010-September 2022). The subtypes of DLBCLs were defined according to Hans algorithm, using immunohistochemistry by three biomarkers (CD10, BCL6, MUM1).
Independent t tests and analyses of variance were used for the comparison of mean values. We employed the SPSS 26.0 program to achieve this. A statistically significant value was set at < .05.
Seventy-five patients (71%) were non-GCB subtype, while thirty-one patients (29%) had the GCB immunosubtype. We have found a significant ( < .05) correlations between DLBCL immunosubtypes and treatment responses on one hand and survival in the other hand. In the GCB subtype, the response rate and survival were significantly improved. A significant association was found between Ki 67 expression and survival on univariate analysis. On multivariate analysis, we note a correlation between Ki 67 expression, DLBCL immunohistochemical subtypes and survival outcome.
Non GCB subtype is associated with poor response to treatment and inferior survival outcome compared to GCB subtype in Moroccan context, especially when combined with high expression of Ki 67 marker.
非霍奇金淋巴瘤最常见的亚型是弥漫性大B细胞淋巴瘤（DLBCL）。生发中心B细胞（GCB）和非生发中心B细胞（非GCB）是利用基于免疫组织化学的方法确定的两种主要的生物学上不同的分子亚型。
本研究的目的是分析DLBCL免疫组织化学亚型（GCB或非GCB）对人口统计学和临床病理参数、化疗反应及生存结果的影响。
这是一项回顾性研究，纳入了摩洛哥非斯哈桑二世大学医院病理科在12年期间（2010年1月至2022年9月）收集的106例DLBCL病例。DLBCL的亚型根据汉斯算法定义，使用三种生物标志物（CD10、BCL6、MUM1）进行免疫组织化学检测。
采用独立t检验和方差分析比较均值。我们使用SPSS 26.0程序来完成此操作。设定统计学显著性值为<0.05。
75例患者（71%）为非GCB亚型，而31例患者（29%）为GCB免疫亚型。我们发现DLBCL免疫亚型一方面与治疗反应之间，另一方面与生存之间存在显著（<0.05）相关性。在GCB亚型中，缓解率和生存率显著提高。单因素分析发现Ki 67表达与生存之间存在显著关联。多因素分析时，我们注意到Ki 67表达、DLBCL免疫组织化学亚型与生存结果之间存在相关性。
在摩洛哥背景下，与GCB亚型相比，非GCB亚型与治疗反应差和生存结果较差相关，尤其是与Ki 67标志物的高表达相结合时。
